Anti-ACVR1 Polyclonal Antibody (HC323014)

Name: Anti-ACVR1 Polyclonal Antibody
Brand: abinScience
SKU: HC323014
Price: 168 USD
Availability: InStock

Datasheet Share product Copy info

Price(USD):

Spec:

50ug
100ug

Number:

Get quote

Overview
Images
References
Datasheet
SDS

Overview

Catalog No.

HC323014

Species reactivity

Human, Mouse, Rat

Applications

ELISA, IHC, WB

Host species

Rabbit

Isotype

IgG

Clonality

Polyclonal

Immunogen

E. coli - derived recombinant Human ACVR1 (Ile208-Lys340).

Target

SKR1, Activin receptor type-1, Activin receptor-like kinase 2, TSR-I, ACVRLK2, ACTR-I, ALK-2, Serine/threonine-protein kinase receptor R1, TGF-B superfamily receptor type I, ACVR1, Activin receptor type I

Purification

Purified by antigen affinity column.

Accession

Q04771

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.

Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.

Product Usage Information

Application	Dilution
ELISA	1:5000-1:20000
IHC	1:50-1:500
WB	1:500-1:2000

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Background

Activin receptor type-1 (ACVR1/ALK-2) is a ~57 kDa protein. Bone morphogenetic protein (BMP) type I receptor that is involved in a wide variety of biological processes, including bone, heart, cartilage, nervous, and reproductive system development and regulation. As a type I receptor, forms heterotetrameric receptor complexes with the type II receptors AMHR2, ACVR2A or ACVR2B. Upon binding of ligands such as BMP7 or GDF2/BMP9 to the heteromeric complexes, type II receptors transphosphorylate ACVR1 intracellular domain. In turn, ACVR1 kinase domain is activated and subsequently phosphorylates SMAD1/5/8 proteins that transduce the signal. In addition to its role in mediating BMP pathway-specific signaling, suppresses TGFbeta/activin pathway signaling by interfering with the binding of activin to its type II receptor.

1. Luo, J. et al. (2010) The Journal of biological chemistry 285, 29588-98. PMID: 20628059

2. Chaikuad, A. et al. (2012) The Journal of biological chemistry 287, 36990-8. PMID: 22977237

3. Renlund, N. et al. (2007) The Journal of endocrinology 195, 95-103. PMID: 17911401

4. Fujimoto, M. et al. (2015) Molecular endocrinology (Baltimore, Md.) 29, 140-52. PMID: 25354296

5. Macías-Silva, M. et al. (1998) The Journal of biological chemistry 273, 25628-36. PMID: 9748228

Note

For research use only.

Images